Yoshihisa Mizukami
Overview
Explore the profile of Yoshihisa Mizukami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimizu J, Murayama M, Mizukami Y, Arimitsu N, Takai K, Miyabe Y
Front Med (Lausanne)
. 2023 Jul;
10:1055753.
PMID: 37435539
Behçet disease (BD) and relapsing polychondritis (RP) are chronic multisystem disorders characterized by recurrent flare-ups of tissue inflammation. Major clinical manifestations of BD are oral aphthae, genital aphthous ulcers, skin...
2.
Arimitsu N, Mizukami Y, Shimizu J, Takai K, Suzuki T, Suzuki N
Mol Cell Neurosci
. 2021 Apr;
112:103614.
PMID: 33845123
Homozygous Dab1 yotari mutant mice, Dab1 (yot/yot) mice, have an autosomal recessive mutation of Dab1 and show reeler-like phenotype including histological abnormality of the cerebellum, hippocampus, and cerebral cortex. We...
3.
Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, et al.
Leukemia
. 2019 Aug;
34(2):499-509.
PMID: 31462733
Studies have shown that mutant calreticulin (CALR) constitutively activates the thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of myeloproliferative neoplasms (MPNs). To further elucidate...
4.
Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, et al.
Leukemia
. 2018 Jun;
33(1):122-131.
PMID: 29946189
Studies have previously shown that mutant calreticulin (CALR), found in a subset of patients with myeloproliferative neoplasms (MPNs), interacts with and subsequently promotes the activation of the thrombopoietin receptor (MPL)....
5.
Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, et al.
Br J Haematol
. 2018 May;
181(6):791-802.
PMID: 29741776
Somatic mutations in the calreticulin (CALR) gene have been found in most patients with JAK2- and MPL-unmutated Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). It has recently been shown that mutant CALR...
6.
Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al.
Blood
. 2016 Jan;
127(10):1307-16.
PMID: 26817954
Recurrent somatic mutations of calreticulin (CALR) have been identified in patients harboring myeloproliferative neoplasms; however, their role in tumorigenesis remains elusive. Here, we found that the expression of mutant but...
7.
Mizukami Y, Abe T, Shibata H, Makimura Y, Fujishiro S, Yanase K, et al.
PLoS One
. 2014 Jun;
9(6):e98319.
PMID: 24927426
Recent studies have revealed negligible immunogenicity of induced pluripotent stem (iPS) cells in syngeneic mice and in autologous monkeys. Therefore, human iPS cells would not elicit immune responses in the...
8.
Nakano K, Watanabe M, Matsunari H, Matsuda T, Honda K, Maehara M, et al.
PLoS One
. 2013 Apr;
8(4):e61900.
PMID: 23626746
Background: The development and validation of stem cell therapies using induced pluripotent stem (iPS) cells can be optimized through translational research using pigs as large animal models, because pigs have...
9.
Fujishiro S, Nakano K, Mizukami Y, Azami T, Arai Y, Matsunari H, et al.
Stem Cells Dev
. 2012 Aug;
22(3):473-82.
PMID: 22889279
In pluripotent stem cells (PSCs), there are 2 types: naive and primed. Only the naive type has the capacity for producing chimeric offspring. Mouse PSCs are naive, but human PSCs...